Introduction. Prostate cancer (PC) is one of the most often diagnosed cancers worldwide. The PC in men influences life quality therefore an early diagnosis provides a better evolution. The gold standard method is the transrectal ultrasoundguided prostate (TRUS-P) biopsy. Material and methods. From May 2016 to December 2021, 328 patients were evaluated using TRUS-P biopsy. The study includes biopsies by core numbers: 43 patients -6core; 44 -10core; 267 -12core and 28 -polysaturated core biopsies (15,18,20). The level of PSA, age, and histological results were assessed. Results. The study includes patients aged 50–90 years. PSA levels ranged from 0.32 to 177,00 ng/ ml, with a mean of 88,66ng/ml. The diagnoses of Adenocarcinoma (AC) were in 214(56,02%) patients; Benign Prostatic Hyperplasia (BPH) in 122(31,93%) patients and Atypical Small Acinar Proliferation (ASAP) in 46 patients (12,04%). The 6-core biopsy revealed that 37,2% (24 patients) had AC, 37,2% (16 patients) had BPH, and 6,97% (3) had ASAP. The 12-core biopsy had shown that 53,18% (142) were diagnosed with AC; 35,2% (94) with BPH; 11,61% (31) with ASAP. The prostatespecific antigen (PSA) average in the patients with AC is 89,4ng/ml (3,18 ng/ml-177,00 ng/ ml). The average PSA level in patients with BPH is 37,16 ng/ml (0,32–74,00 ng/ml). An average of 22,99ng/ml (3,29–44,70 ng/ml) was found in the patients diagnosed with ASAP. There were 27 cases of AC in patients under the age of 60, with 4,1% (8 patients) diagnosed between 2016 and 2018, and 9,94% (19) diagnosed between 2019 and 2021. Conclusions. The 10 and 12 core TRUS-P biopsies are efficient in the identification of ASAP forms, which can be suggestive of PC, making an early diagnosis possible. The study also shows that the identification rate of PC in patients under 60 years old is increasing.